There are currently 25 vaccines to fight COVID-19 in clinical evaluation, another 139 vaccines in a pre-clinical stage, and many more being researched.
But many of those vaccines, if they are at all successful, might not produce an immune response in portions of the population. That’s because some people’s bodies will react differently to the materials in the vaccine that are supposed to stimulate virus-fighting T cells.
And so just figuring out how much coverage a vaccine has, meaning, how many people it will stimulate to mount an immune response, is a big part of the vaccine puzzle.
With that challenge in mind, scientists at Massachusetts Institute of Technology on Monday unveiled a machine learning approach that can predict the probability that a particular vaccine design will reach a certain proportion of the population. That doesn’t mean they can guarantee its effectiveness, but the scientists’ work can aid in knowing up-front whether a given vaccine will have large gaps in who it can help.
The good news is, the MIT scholars have used their approach to design a novel COVID-19 vaccine on the computer that has far better coverage than many of the designs that have been published in the literature this year. They’re now testing the design in animals.
The bad news is, there could very well be large gaps in coverage of some of the existing vaccines already being explored by companies and labs, according to one of the authors of the report, David K. Gifford, who is with MIT’s Computer Science and Artificial Intelligence Laboratory.
“While they may protect more than 50% of the population, certain individuals and older individuals may not be protected,” Gifford told ZDNet in an email, when asked about vaccines currently under trial and in development.
The long path to a vaccine
Vaccines in development were not the direct subject of the work. Most of those vaccines are closed designs; no one knows exactly how they are composed. Instead, Gifford and colleagues designed vaccines from scratch, and then analyzed how effective they are, and extrapolated the findings to a group of vaccines whose composition is known.
Based on that, one can infer there might be problems with vaccines whose exact composition is not known.
It must be borne in mind that any in silico vaccine design such as the kind discussed here is only the beginning of a process that can take years to go through in vivo testing, in animals and then in humans, to establish both safety (non-toxicity), and efficacy, meaning that it actually confers a significant immune response.
But the work shows the ability of large computer models to dramatically speed up the initial work of searching through many, many possible combinations within a universe of possible ingredients, a search that can itself take years at the front end of a drug development pipeline.
This is the latest in large-scale, in-silico efforts against pathogens seen this year from MIT. Back in March, ZDNet reported on how MIT scientists used large-scale machine learning to search many combinations of compounds to come up with a novel antibiotic for a germ nothing else could kill.
Image Credit: Amanda Scott/Envato
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
Researchers from Duke University are developing a flu shot with the new technology that was used for two coronavirus vaccines. Both the Pfizer-BioNTech and the Moderna shots use part of the virus's genetic code [...]
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19. In a paper published in the journal Nanoscale, [...]
Researchers have developed a new superbug-destroying coating that could be used on wound dressings and implants to prevent and treat potentially deadly bacterial and fungal infections. The material is one of the thinnest antimicrobial [...]
The U.S. is recommending a "pause" in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. In a joint statement Tuesday, the Centers for Disease Control [...]
The South African coronavirus variant is better at "breaking through" the defences of the Pfizer/BioNTech vaccine than other forms of the virus, Israeli experts said Sunday. However, one of the authors told AFP that [...]
EPFL scientists have developed AI-powered nanosensors that let researchers track various kinds of biological molecules without disturbing them. The tiny world of biomolecules is rich in fascinating interactions between a plethora of different agents [...]
A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Federal Institute of Virology and Immunology (IVI) have assessed virus growth and activation of the cellular [...]
Researchers at Brown University have succeeded in creating the first wireless, implantable, rechargeable, long-term brain-computer interface. The wireless BCIs have been implanted in pigs and monkeys for over 13 months without issue, and human [...]
The coronavirus outbreak made household names of companies like Moderna Inc. and BioNTech SE, whose shots offered hope for ending the pandemic. Now a new wave of vaccines is on the horizon that may get the [...]
Researchers at the University of Southampton have developed a new way of using nanomaterials to identify and enrich skeletal stem cells—a discovery which could eventually lead to new treatments for major bone fractures and [...]
In March 2020, Hannu Rajaniemi pivoted his biotech company Helix Nanotechnologies' focus from cancer therapies to Covid-19 vaccines. The role biotech start-ups can play in a pandemic Rajaniemi originally co-founded Helix Nanotechnologies in Cambridge, Massachusetts in [...]
The rapid mass testing strategy costing just £1 a day per child can get children back to school and economies up and running, according to experts. That is the small price of the [...]
Covid-19 vaccines are incredibly good at preventing severe symptoms and hospitalization, but they’re probably less effective at stopping transmission. To do that, we might need a different kind of vaccine altogether. Because SARS-CoV-2 is [...]
For many scientists, challenging the idea that SARS-CoV-2 has natural origins is seen as career suicide. But a vocal few say it shouldn't be disregarded or lumped in with conspiracy theories. Nikolai Petrovsky was scrolling [...]
The most widely used approach to testing for COVID-19 requires a polymerase chain reaction (PCR) test, which involves taking a swab of the back of the throat and far inside the nose. In a [...]